Comparison of concurrent alterations of other genes between MDS patients with and without the SRSF2 mutation
| Genes (no. of patients tested) . | No. (%) of patients with mutation of other gene* . | P . | |
|---|---|---|---|
| SRSF2-wild patients . | SRSF2-mutated patients . | ||
| JAK2 (n = 209) | 2 (1.1) | 1 (3.2) | .384 |
| MLL/PTD (n = 216) | 4 (2.2) | 2 (5.9) | .240 |
| K-RAS (n = 231) | 3 (1.5) | 0 (0) | 1.000 |
| N-RAS (n = 232) | 8 (4.0) | 1 (2.9) | 1.000 |
| RUNX1 (n = 233) | 20 (10.1) | 10 (29.4) | .004 |
| FLT3/ITD (n = 233) | 6 (3.0) | 0 (0) | .596 |
| WT1 (n = 228) | 1 (0.5) | 0 (0) | 1.000 |
| IDH1 (n = 233) | 3 (1.5) | 0 (0) | 1.000 |
| IDH2 (n = 233) | 5 (2.5) | 7 (20.6) | < .001 |
| ASXL1 (n = 233) | 39 (19.6) | 16 (47.1) | < .001 |
| DNMT3 (n = 230) | 11 (5.6) | 2 (5.9) | 1.000 |
| EZH2 (n = 217) | 19 (10.4) | 5 (14.7) | .549 |
| Genes (no. of patients tested) . | No. (%) of patients with mutation of other gene* . | P . | |
|---|---|---|---|
| SRSF2-wild patients . | SRSF2-mutated patients . | ||
| JAK2 (n = 209) | 2 (1.1) | 1 (3.2) | .384 |
| MLL/PTD (n = 216) | 4 (2.2) | 2 (5.9) | .240 |
| K-RAS (n = 231) | 3 (1.5) | 0 (0) | 1.000 |
| N-RAS (n = 232) | 8 (4.0) | 1 (2.9) | 1.000 |
| RUNX1 (n = 233) | 20 (10.1) | 10 (29.4) | .004 |
| FLT3/ITD (n = 233) | 6 (3.0) | 0 (0) | .596 |
| WT1 (n = 228) | 1 (0.5) | 0 (0) | 1.000 |
| IDH1 (n = 233) | 3 (1.5) | 0 (0) | 1.000 |
| IDH2 (n = 233) | 5 (2.5) | 7 (20.6) | < .001 |
| ASXL1 (n = 233) | 39 (19.6) | 16 (47.1) | < .001 |
| DNMT3 (n = 230) | 11 (5.6) | 2 (5.9) | 1.000 |
| EZH2 (n = 217) | 19 (10.4) | 5 (14.7) | .549 |
Number (%) of patients showing the specific gene mutation listed in the far left column among the SRSF2-wild or SRSF2-mutated group.